Production (Stage)
Kyverna Therapeutics, Inc.
KYTX
$3.28
-$0.11-3.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -207.05% | -300.75% | -463.45% | -- | -- |
| Total Depreciation and Amortization | 127.97% | 149.18% | 164.58% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.97% | 130.06% | 190.37% | -- | -- |
| Change in Net Operating Assets | 1,006.03% | 1,757.59% | 415.99% | -- | -- |
| Cash from Operations | -142.01% | -177.62% | -204.87% | -- | -- |
| Capital Expenditure | -89.51% | -509.12% | -4,917.50% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.92% | -447.27% | -642.39% | -- | -- |
| Cash from Investing | 77.67% | -1,732.18% | -525.86% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -136.89% | -147.03% | -196.49% | -- | -- |
| Issuance of Common Stock | -99.94% | 114,090.64% | 509,859.70% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 89.16% | -125.57% | -- | -- | -- |
| Cash from Financing | -100.36% | 915.03% | 872.37% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -197.99% | 470.51% | 468.36% | -- | -- |